Gemcitabine in advanced renal cell carcinoma A phase II study of the National Cancer Institute of Canada Clinical Trials Group

摘要: Summary Background Gemcitabine (2', 2'-difluorodeoxycytidine; dFdC) an anticancer agent with activity in preclinical models, was felt to be a promising new chemotherapy drug which warranted testing patients advanced renal cell carcinoma Methods Eighteen histologically proven metastatic or locally recurrent and bidimensionally measurable disease were accrued phase II study of gemcitabine administered intravenously on days 1, 8 15 28 day treatment cycle. Initial doses 800 mg/m2; subsequent cycles escalated maximum 1250 mg/m2, toxicity permitting. Results One partial response seen for rate 6%. Hematologic not severe this dosing schedule; however, two developed dyspnea bronchospasm after repeated injections drug. Conclusions The dose schedule employed results only modest carcinoma. Investigators should aware the possibility developing shortly administration.